8 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 8 of 8 clinical reviews.
Health-economic analysis of dutasteride 0.5 mg versus finasteride 1 mg for androgenetic alopecia based on the Eun 2010 phase III RCT, including cost per QALY modeling, payer coverage, and relative value for patients.
Long-term follow-up analysis of the Eun 2010 dutasteride vs finasteride trial for androgenetic alopecia: durability of hair count gains, late safety signals, and what post-trial data tell us about sustained 5-alpha reductase inhibition.
A detailed breakdown of the Eun 2010 trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, including effect sizes, time-course data, and response distribution.
Deep-dive into subgroup analyses from the 917-patient Eun et al. 2010 trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, examining response by age, baseline severity, and hair count.
A deep-dive overview of the 2010 Eun et al. randomized trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, covering methodology, results, limitations, and clinical relevance.
A critical appraisal of the 2010 Eun et al. randomized trial comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, examining enrollment biases, follow-up gaps, statistical caveats, and conflict-of-interest considerations.
A detailed methodology analysis of the 2010 Eun et al. RCT comparing dutasteride 0.5 mg to finasteride 1 mg for androgenetic alopecia, examining randomization, blinding, endpoint definition, and statistical approach.
A clinical-practice analysis of the Eun 2010 phase III RCT showing dutasteride 0.5 mg superiority over finasteride 1 mg for androgenetic alopecia, with guideline impact and prescribing implications.